BR112022010687A2 - ATTENUATED AVIAN REOVIRUS STRAINS 94826 C140 AND 96139 C140 - Google Patents

ATTENUATED AVIAN REOVIRUS STRAINS 94826 C140 AND 96139 C140

Info

Publication number
BR112022010687A2
BR112022010687A2 BR112022010687A BR112022010687A BR112022010687A2 BR 112022010687 A2 BR112022010687 A2 BR 112022010687A2 BR 112022010687 A BR112022010687 A BR 112022010687A BR 112022010687 A BR112022010687 A BR 112022010687A BR 112022010687 A2 BR112022010687 A2 BR 112022010687A2
Authority
BR
Brazil
Prior art keywords
avian reovirus
attenuated
avian
reovirus
tenosynovitis
Prior art date
Application number
BR112022010687A
Other languages
Portuguese (pt)
Inventor
S Sellers Holly
Original Assignee
Univ Georgia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgia filed Critical Univ Georgia
Publication of BR112022010687A2 publication Critical patent/BR112022010687A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12061—Methods of inactivation or attenuation
    • C12N2720/12064—Methods of inactivation or attenuation by serial passage

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

CEPAS DE REOVÍRUS AVIÁRIO ATENUADO 94826 C140 E 96139 C140. Isolados atenuados de reovírus aviários associados a artrite viral/tenossinovite em aves domésticas são apresentados, incluindo a cepa de reovírus aviário 94826 C140 depositada na ATCC sob a designação de patente PTA-126077 e a progênie ou os derivados da mesma e a cepa de reovírus aviário 96139 C140 depositada na ATCC sob a designação de patente PTA-126078 e a progênie ou os derivados da mesma. Composições e métodos para administrar os isolados ou as composições como vacinas para o controle da artrite viral/tenossinovite induzida por reovírus em aves da ordem Galliformes também são apresentados.ATTENUATED AVIAN REOVIRUS STRAINS 94826 C140 AND 96139 C140. Attenuated isolates of avian reoviruses associated with viral arthritis/tenosynovitis in poultry are presented, including the avian reovirus strain 94826 C140 deposited with the ATCC under patent designation PTA-126077 and the progeny or derivatives thereof and the avian reovirus strain 96139 C140 filed with the ATCC under patent designation PTA-126078 and progeny or derivatives thereof. Compositions and methods for administering the isolates or the compositions as vaccines for the control of viral arthritis/reovirus-induced tenosynovitis in birds of the order Galliformes are also disclosed.

BR112022010687A 2019-12-02 2020-12-01 ATTENUATED AVIAN REOVIRUS STRAINS 94826 C140 AND 96139 C140 BR112022010687A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962942426P 2019-12-02 2019-12-02
PCT/US2020/062651 WO2021113206A1 (en) 2019-12-02 2020-12-01 Attenuated avian reovirus strains 94826 c140 and 96139 c140

Publications (1)

Publication Number Publication Date
BR112022010687A2 true BR112022010687A2 (en) 2022-08-23

Family

ID=76221714

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010687A BR112022010687A2 (en) 2019-12-02 2020-12-01 ATTENUATED AVIAN REOVIRUS STRAINS 94826 C140 AND 96139 C140

Country Status (7)

Country Link
US (1) US20230000972A1 (en)
EP (1) EP4069289A4 (en)
JP (1) JP2023504225A (en)
CN (1) CN114828883A (en)
BR (1) BR112022010687A2 (en)
MX (1) MX2022006546A (en)
WO (1) WO2021113206A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116478937B (en) * 2023-06-12 2023-08-18 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） Gene III avian reovirus variant and application thereof in preparing vaccine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016009747A (en) * 2014-01-29 2016-11-09 Univ Georgia Avian reovirus vaccines.
CA3026241A1 (en) * 2016-06-02 2017-12-07 Steven Baranowitz Prevention and treatment of viral infections

Also Published As

Publication number Publication date
EP4069289A4 (en) 2023-11-29
EP4069289A1 (en) 2022-10-12
WO2021113206A1 (en) 2021-06-10
MX2022006546A (en) 2022-07-01
US20230000972A1 (en) 2023-01-05
CN114828883A (en) 2022-07-29
JP2023504225A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
BARBERIS et al. History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccines
BR112019023758A2 (en) newcastle disease virus and its uses
BR112012004806B8 (en) immunogenic compositions that include modulators of tlr activity, method to increase the effectiveness of said composition and use
BR112015009216A2 (en) compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, and use of a pharmaceutical composition
BR112017026287A2 (en) hydroxypropyl beta-cyclodextrin compositions and methods
BR112012033227A2 (en) glucagon analogs
BRPI0707300A8 (en) VACCINE AGAINST DIVIDED INFLUENZA VIRION OR PURIFIED SURFACE ANTIGEN AND METHOD FOR THE PREPARATION OF AN IMMUNOGENIC COMPOSITION
CO2021002977A2 (en) Dimethylaminoazetidinamines as jak inhibitors
BR112018069601A2 (en) substituted indoline derivatives as dengue viral replication inhibitors
BR112016003317A2 (en) avian adenovirus vaccine
BR112018068956A2 (en) substituted indole derivatives as dengue viral replication inhibitors
BR112018070962A2 (en) innovative bacterial species
UY37742A (en) INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE DENGUE VIRIC REPLICATION
BR112022010687A2 (en) ATTENUATED AVIAN REOVIRUS STRAINS 94826 C140 AND 96139 C140
BR112017000519A2 (en) "immunogenic composition, and method for protecting a mammal against meningococcal infection"
BR112021012616A2 (en) Ergothioneine-producing strain and method for screening it
BR112017011552A2 (en) fgf21 derivatives and their use
BR112014011443A2 (en) lactic acid bacteria and their use as feed supplements for poultry
MX2020003732A (en) Fused ring derivative as a.
BR112022019519A2 (en) TREATMENT
BRPI0516542A (en) composition of vaccine effective in preventing or ameliorating infection with avian influenza virus; method to prevent or improve the outbreak of infection by avian influenza virus
BR112017013999A2 (en) "composition derived from a bifidobacterium"
BR112019000453A2 (en) combination of ceftibutene and clavulanic acid for use in treating bacterial infections
CL2021002727A1 (en) Vaccine with vfpc subunits
BR112022019207A2 (en) VACCINE COMPOSITIONS FOR CORONA VIRUSES AND METHODS OF THEIR USE